Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase 3 2Phase 1/2 2Phase 4 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 685Breast Neoplasms 584Neoplasms 468Colorectal Neoplasms 298Prostatic Neoplasms 262Neoplasm Metastasis 256Melanoma 241Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 195Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 141Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Head and Neck Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Small Cell Lung Carcinoma 95Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 76Triple Negative Breast Neoplasms 72

Interventions

fluzoparib 1enzalutamide 1apatinib 1Prednisone 1Pluvicto 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT05219500 2026-04-03

TATCIST

Fusion Pharmaceuticals Inc.

Phase 2 Active not recruiting
115 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03042312 2021-03-24

RESIST-PC

Endocyte

Phase 2 Terminated
71 enrolled 15 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡